In vivo pathways of natural retinoid metabolism and elimination have not been well characterized in primary myeloid cells, even though retinoids and retinoid receptors have been strongly implicated in regulating myeloid maturation. With the use of a upstream activation sequence-GFP reporter transgene and retrovirally expressed Gal4-retinoic acid receptor a in primary mouse bone marrow cells, we identified 2 distinct enzymatic pathways used by mouse myeloid cells ex vivo to synthesize retinoic acid receptor a ligands from free vitamin A metabolites (retinyl acetate, retinol, and retinal). Bulk Kit + bone marrow progenitor cells use diethylaminobenzaldehydesensitive enzymes, whereas bone marrow-derived macrophages use diethylaminobenzaldehydeinsensitive enzymes to synthesize natural retinoic acid receptor a-activating retinoids (all-trans retinoic acid). Bone marrow-derived macrophages do not express the diethylaminobenzaldehyde-sensitive enzymes Aldh1a1, Aldh1a2, or Aldh1a3 but instead, express Aldh3b1, which we found is capable of diethylaminobenzaldehyde-insensitive synthesis of all trans-retinoic acid. However, under steady-state and stimulated conditions in vivo, diverse bone marrow cells and peritoneal macrophages showed no evidence of intracellular retinoic acid receptor a-activating retinoids, despite expression of these enzymes and a vitamin A-sufficient diet, suggesting that the enzymatic conversion of retinal is not the rate-limiting step in the synthesis of intracellular retinoic acid receptor a-activating retinoids in myeloid bone marrow cells and that retinoic acid receptor a remains in an unliganded configuration during adult hematopoiesis.
Introduction
Retinoid receptors are nuclear hormone receptors that are dynamically regulated during terminal myeloid maturation and influence hematopoietic stem cell self-renewal and differentiation [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . There are 2 types of retinoid receptors-RARs and RXRs-both of which have 3 subtypes (a, b, g). RARs heterodimerize with RXR, and this heterodimer recognizes RA response elements in promoter/enhancer sequences of target genes. Retinoid receptor transcriptional activity is ligand dependent: in the absence of ligand, RAR/RXR heterodimers bind to corepressors (e.g., nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors); in the presence of ligand, retinoid receptors release corepressors, recruit coactivators, and activate transcription activity [13] . ATRA is thought to be the principal natural ligand for RARA and is a critical therapy for the treatment of patients with APL (a leukemia with pathognomonic expression of the fusion oncoprotein PML-RARA) [14] [15] [16] [17] [18] . However, the enzymatic pathways that regulate natural retinoids have not been well defined in primary hematopoietic cells.
ATRA is synthesized from vitamin A through 2 sequential steps. Vitamin A (principally, protein-bound serum retinol) is oxidized by ADHs to yield retinal (there are many isoforms that appear redundant). Retinal is then irreversibly oxidized by an ALDH to generate retinoic acid [19, 20] . At least 19 different human ALDHs have been identified. Among them, ALDH1A1, ALDH1A2, and ALDH1A3 have been shown to oxidize all trans-retinal to ATRA with high affinity (K m is ,0.1 mM, 0.7 mM, 0.2 mM, respectively) [21] [22] [23] [24] and have been implicated as the rate-limiting step in ATRA synthesis [25, 26] . Intracellular levels of ATRA are also regulated by elimination via P450 enzymes (principally, CYP26 family) [27] .
Multiple ALDH inhibitors have been characterized. In specific, DEAB is an ALDH inhibitor commonly used as a negative control in the Aldefluor assay, which is used for identification, evaluation, and isolation of stem and progenitor cells based on their expression of ALDH. DEAB behaves as a classic substrate for ALDH3A1, as a covalent inhibitor for ALDH2 and ALDH1A2, and as an intermediate between substrate and inhibitor for 1 . Correspondence: Dept. Internal Medicine, Washington University School of Medicine, 660 South Euclid Ave., Box 8007, St. Louis, MO 63110, USA. E-mail: jwelch@dom.wustl.edu ALDH1A1, ALDH1A3, ALDH1B1, and ALDH5A1 [28] . More recently, WIN 18446 was found to be a potent reversible inhibitor of ALDH1A1 and ALDH1A3 (IC 50 = 102 6 2 nM and 187 6 1 nM) and an efficient, time-dependent inhibitor (k inact = 22.0 6 2.4 h-1, K I = 1026 6 374 nM; where k inact = maximal inactivation and K I = concentration at 50% K inact ) of ALDH1A2 [29] .
To understand the synthesis and metabolism of naturally occurring RARA ligands in primary mouse bone marrow cells, we used a UAS-GFP reporter mouse, which we described recently [30] . The UAS promoter (upstream-activating sequence) is recognized by the yeast Gal4 transcription factor but not by mammalian proteins [31] . When we transduce UAS-GFP bone marrow cells with retroviruses, which express a fusion of the Gal4 DNA-binding domain and the RARA ligand-binding domain, cells with intracellular RARA ligands activate the GFP reporter.
We found that immature mouse Kit + bone marrow progenitor cells (Kit + progenitor cells) and mature mouse BMMw used different pathways to synthesize active RARA ligands. The former uses canonical ALDH pathways that are inhibited by DEAB (likely, Aldh1a1, Aldh1a2, and Aldh1a3), whereas BMMw use DEAB-insensitive enzymes. Through expression-array profiling, we identified Aldh3b1 as a likely candidate and found that overexpression of this gene in 293T cells could synthesize ATRA and specifically activate the UAS-GFP/Gal4-RARA reporter. However, in vivo, we observed no evidence of naturally occurring retinoids in bone marrow cells or in peritoneal macrophages, despite a vitamin A-sufficient diet, suggesting that the synthesis of intracellular RARA ligands is tightly controlled in hematopoietic cells but that expression of these enzymes is not the rate-limiting step for in vivo retinoid synthesis.
MATERIALS AND METHODS

Reagents
ATRA, RyA, retinol, retinal, daidzin, cyanamide, DEAB, citral, 5FU, phenylhydrazine, neuraminidase, octanal, NAD + , and NADH were from SigmaAldrich (St. Louis, MO, USA). Disulfram was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Imject Alum was from Thermo Fisher Scientific (Grand Island, NY, USA). BMS493, recombinant mouse Scf, Flt3, IL-3, Tpo, Liarozole, and Talarozole were purchased from R&D Systems (Minneapolis, MN, USA). Ro41-5253 was purchased from Enzo (Farmingdale, NY, USA). M-CSF was produced as described [32] . G-CSF was from Amgen (Millstadt, IL, USA 
Constructs
The plasmids pCMX-Gal4-RARA and pCMX-Gal4-RXRA were generous gifts from Dr. Christopher K. Glass (University of California at San Diego, CA, USA) and Mercedes Ricote (Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain). The plasmid pPAX6m-Gal4-VP16 was a gift from Thomas Perlmann (Ludwig Cancer Center, Stockholm, Sweden). MSCV-Gal4-RARA-IC has been described previously [30] . Human ALDH3B1 plasmids were kind gifts from Akio Kihara (Hokkaido University, Sapporo, Japan) [33] . MSCV-STRA6-IRES-Cerulean was generated by cloning the NheI/XhoI Cerulean fragment from Addgene plasmid 15214 into MSCV-IRES-YFP, replacing the YFP sequence. STRA6 cDNA was a kind gift from Marcin Golczak (Case Western Reserve University, Cleveland, Ohio), and the XmnI/XhoI fragment containing the entire cDNA was blunt cloned into MSCV-IRES-Cerulean. The insertion was confirmed to be identical to the STRA6 reference sequences in the Ensembl data base. Aldh3b1, Aldh7a1, Aldh8a1, Aldh9a1, Akr1a4, Akr1b8, and 2810405K02Rik expression constructs were purchased from OriGene.
Mice
UAS-GFP mice were bred as described and maintained on standard chow (PicoLab 20, which contains 15 IU/gm vitamin A; LabDiet, St. Louis, MO, USA) [30] . ATRA was administered by oral gavage, daily for 3 d, and suspended in sterile corn oil, 50 mg/mouse, 100 mg/mouse, or 200 mg/mouse. G-CSF (300 mg/kg/d 3 3 d), Phenylhydrazine (60 mg/kg once), Neuraminidase (0.05 U/mouse once), 5FU (4.5 mg/mouse once), or injections of 100 mg (4-hydroxy-3-nitrophenyl) acetyl-chicken g globulin in alum were administered as described previously [34] [35] [36] [37] [38] [39] [40] [41] [42] . There were 5 mice each in control and experiment groups. Each experiment was done at least twice. All of the mice used for experiments were 6-8 wk old. Both genders were used. As gender-specific differences were not observed, the data were combined. All of the mice were cared for in the Experimental Animal Center of Washington University School of Medicine. The Washington University Animal Studies Committee approved all animal experiments.
Retrovirus production and transduction
Calcium chloride transfection and low-passage 293T cells were used for the virus package, as described [43] . In vitro ALDH assay FLAG-mouse ALDH3B1 (33) and 33 FLAG-human ALDH3B1 were expressed in 293T cells using calcium phosphate transfection, as above. 293T cells, BMMw, and Kit + progenitor cells were lysed with radioimmunoprecipitation assay buffer (50 mM Tris-HCl, NaCl 150 mM, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA). Protein was quantified by a bicinchoninic acid quantification kit (Thermo Fisher Scientific).
The assay was performed as described [33] . Octanal was used as substrate. Protein (1 ml) was incubated with 500 mM NAD + and Octanal (1, 5, 10, 33, 50, and 100 mM) in 50 ml buffer B [50 mM Tris-HCl (pH 8.5), 150 mM NaCl, 10% glycerol, and 0.1% Triton X-100] at 37°C. The reaction was monitored by measuring the fluorescence of the NADH product (excitation at 356 nm and emission at 460 nm) using Synergy 2 (BioTek, Winooski, VT, USA). A linear, standard curve was obtained from 0, 5, 10, 25, and 100 mM NADH and used to quantify the NADH produced in the assay.
Liquid chromatography/MS/MS analysis of ATRA
Retinoids were extracted from media or cell pellets by methanol extraction. Media (200 ml) were mixed with 300 ml methanol and 10 ng 14,15-DHET-d 11 standard (Cayman Chemical, Ann Arbor, MI, USA), vortexed and centrifuged for 5 min, and the supernatant was diluted with 100 ml water and analyzed. Cell pellets were mixed with 100 ml water, 400 ml methanol, and 10 ng 14,15-DHET-d 11 standard; vortexed; and centrifuged for 5 min, and the supernatant was diluted with 300 ml water and analyzed. Three-point ATRA (SigmaAldrich) calibration standard samples (0.2, 0.8, and 10 ng), containing the internal standard (10 ng), were also prepared for the absolute quantification. Diluted urine and calibration samples (50 ml) were injected onto a C18 column (BetaSil 100 3 2.1 mm, 3 mm; Thermo Electron, Thermo Fisher Scientific, Keystone, PA, USA),connected to an online trapping LC-20AD HPLC system (Shimadzu, Kyoto, Japan), interfaced with an API 4000 triplequadruple mass spectrometer (Applied Biosystems, Foster City, CA, USA) for ATRA analysis. Acetonitrile and water containing 10 mM ammonium acetate were used for chromatographic separation of ATRA and the internal standard. The solvent gradient was at 70% acetonitrile for 2 min and then programmed to 99% acetonitrile for 5 min at a flow rate of 0.7 ml/min. Negative ion electrospray multiple reaction monitoring mode (monitoring Q1/Q3 ions: 299/255 for ATRA and 348/207 for 14,15-DHET-d 11 ) was controlled by Analyst software (Applied Biosystems) for quantification of ATRA.
Knockdown ALDH3B1 in BMMw
On d 1, bone marrow macrophages were plated at 100,000 cells/well in 24-well plates in 200 ml. A 300 ml mixture of retrovirus containing 0.25 ml polybrene and 7.5 ml HEPES was added and cells centrifuged as above. After 1 h of incubation, cells were transfected with Aldh3b1 siRNA. Viromer Green (2.25 ml) was mixed with 410 ml solution F (provided by manufacturer). siRNA (4.5 ml; 20 mM) was mixed with 28 ml solution F. These 2 dilutions were then mixed and incubated for 10 min at room temperature, and 70 ml was added in triplicate wells to cells in 500 ml media. Four hours later, an additional 250 ml media was added. On d 3, retinal was added to 100 nM. On d 5, cells were collected for analysis. 
Expression array profiling
Expression profiling was done using Affymetrix exon 1.0 arrays, as described previously [44] . Data have been deposited in Gene Expression Omnibus (GSE76060).
Data analysis
Flow cytometry data were analyzed with FlowJo software version 9 (Tree Star, Ashland, OR, USA). Statistical analysis was performed using Prism (GraphPad Software, San Diego, CA, USA) and Excel (Microsoft, Seattle, WA, USA). t-Test and ANOVA tests were performed, as appropriate. All studies were performed in triplicate, unless otherwise indicated. Error bars represent SD. Data points without error bars have SD below GraphPad's limit to display.
RESULTS
DEAB-sensitive and -insensitive pathways of retinoid synthesis
To determine pathways used for retinoid synthesis in different mouse bone marrow cells, we applied an assay using a UAS-GFP reporter and a coexpressed fusion of the DNA-binding domain from the yeast Gal4 transcription factor and the ligand-binding domain from RARA (Gal4-RARA). This fusion recognizes the UAS promoter, which is not activated by mammalian transcription factors.
Initial studies with the UAS-GFP reporter were performed in a cell line that could be easily transfected-293T. We found that cotransfection of the UAS-GFP reporter and Gal4-RARA plasmids resulted in a modest but reproducible increase in GFP (Fig. 1A , column 3 vs. 1). Inhibition of P450 by liarozole treatment augmented the GFP reporter activity (Fig. 1A, column 4) , and the ALDH antagonist DEAB abrogated the effects of liarozole (Fig. 1A,, columns 5-7 ). This suggests that in 293T cells, natural RARA ligands are synthesized via enzymatic conversion of serumavailable vitamin A, and their intracellular levels are balanced through a process of simultaneous synthesis and then elimination via P450 enzymes, as has been published previously (Fig. 1B,  schema) [27] .
To determine whether primary hematopoietic cells use similar retinoid synthesis and elimination pathways, we used UAS-GFP transgenic mice [30] . We initially transduced MACS-selected Kit + bone marrow progenitor cells (Kit + progenitor cells) from UAS-GFP mice ex vivo with MSCV-Gal4-RARA-IC. These cells represent a heterogeneous population of myeloid and erythroid progenitor cells that can be maintained ex vivo in Scf, IL-3, Flt3, and Tpo and retain high numbers of CFUs after 1 wk in culture (;1 in 10 cells forms colonies in myeloid methylcellulose). We found that when grown in 15% FCS, these cells did not synthesize sufficient intracellular RARA ligands to induce the GFP reporter, even with liarozole treatment, although they did respond to 
Niu et al. Retinoid synthesis in hematopoietic cells
exogenous ATRA (Fig. 1C, columns 1 and 2 , and data not shown). This system is highly sensitive to available ATRA, with an EC 50 of 0.36 6 0.14 nM [30] . Serum levels of vitamin A (principally retinol) are ;1 mM in humans and mice, with lower concentrations of RyA (;200 nM) and retinal (;300 nM) [45] [46] [47] [48] [49] [50] [51] . We supplemented the medium with different forms of vitamin A, which resulted in a dose-dependent response (Fig. 1C  and D) . This response could be augmented by inhibition of P450 activity (liarozole treatment, green) and was inhibited by DEAB treatment (red; Fig. 1C and D) . Similar results were observed using a second P450 inhibitor with greater Cyp26 specificity (talarozole, blue; Fig. 1D ). These results demonstrate that primary Kit + progenitor cells are capable of synthesizing transcriptionally active retinoids when supplied with exogenous, free vitamin A metabolites, RyA, and retinal.
We repeated these studies using a second primary cell type-BMMw-which unlike the Kit + progenitor cells, are terminally differentiated and have undergone cell-cycle arrest. When BMMw were transduced with MSCV-Gal4-RARA-IC, we observed that they could synthesize RARA ligands from exogenously added RyA and retinal (50-300 nM) but again, could not make use of serum-available forms of vitamin A ( Fig. 1E and F) . However, this process was insensitive to DEAB (Fig. 1F, red) , liarozole (Fig. 1E, green) , and talarozole (Fig. 1F,  blue) , suggesting that BMMw use alternative enzymatic pathways to synthesize and eliminate transcriptionally active retinoids from vitamin A metabolites.
To validate these results, we treated Kit + progenitor cells and BMMw in parallel and again, observed that DEAB inhibited retinoid synthesis in Kit + progenitors but not in BMMw ( Fig. 2A) . With the use of a series of ALDH inhibitors, we found that each could inhibit synthesis of RARA ligands from 3 different vitamin A precursors (RyA, retinol, and retinal) in the Kit + progenitor cells, but they had a very limited effect on retinoid synthesis in BMMw (Fig. 2B) . A new compound-WIN 18446-has recently shown strong inhibition activity of all 3 ALDH1A family enzymes [29] . Synthesis of RARA ligands from free retinal and retinol in BMMw was resistant to WIN 18446, as well (Fig. 2C) . These data strongly suggested that BMMw use alternative enzymatic pathways other than the ALDH1A family to synthesize active RARA ligands.
To investigate the kinetics of the active RARA ligand formation in BMMw, we compared the rate of UAS-GFP reporter activation in BMMw treated with retinol, retinal, or ATRA (each 300 nM; Fig.  2D and E). We observed similar kinetics of UAS-GFP reporter activation among ATRA, retinal, and retinol in BMMw, suggesting that the enzymatic conversion of retinal and retinol must occur on a time scale that is faster than the sensitivity of the ex vivo assay.
We assessed a second mature myeloid cell population ex vivo by differentiating Kit + progenitor cells into granulocytes in the presence of G-CSF and Scf (Supplemental Fig. 1A ). We found that these cells had an intermediate phenotype compared with BMMw; we observed no difference with liarozole treatment and only a mild reduction with DEAB treatment.
Expression of ALDHs in primary bone marrow cells
With the use of RT-PCR, we assessed RNA levels of the 3 ALDH1A enzymes described to have retinaldehyde dehydrogenase activity and to be DEAB and WIN 18446 sensitive [29, 52, 53] . Not surprisingly, we detected expression of Aldh1a1, Aldh1a2, and Aldh1a3 in Kit + progenitor cells but not in BMMw (Fig. 3A) . We examined an extended panel of Aldh genes by RT-PCR in Kit + progenitor cells and in ex vivo-derived granulocytes and noted similar expression levels of Aldh1a1 but reduced expression of Aldh1a2 and Aldh1a3, consistent with the intermediate sensitivity to DEAB that we observed previously (Supplemental Fig. 1B) .
To identify additional enzymes that might contribute to DEABinsensitive retinoid synthesis in BMMw, we compared gene expression in Kit + progenitor cells with BMMw by Affymetrix array profiling. We identified 1217 genes that were annotated as enzymes or as involved in enzymatic pathways and were differentially expressed in BMMw vs. Kit + progenitor cells (P , 0.01; Fig. 3B ). We hand curated this list and identified 5 genes that were more highly expressed in BMMw, annotated with lipid-binding capacity and dehydrogenase function, or were largely uncharacterized (Fig. 3C ). None of these had been implicated previously in retinaldehyde dehydrogenase activity, although ALDH3B1 has been shown to oxidize lipid-derived aldehydes generated in the plasma membrane [33] and is known to be expressed in kidney, liver, cerebral astrocytes, and histocytes [54, 55] . We validated the expression difference of Aldh3b1 and Aldh9a1 using quantitative RT-PCR and included an extended panel of additional Aldh genes (Fig. 3D) . Again, Aldh1a1, Aldh1a2, and Aldh1a3 were noted to be expressed at lower levels in BMMw vs. Kit + progenitor cells.
Identification of the enzyme required in ATRA synthesis in BMMw
To identify enzymes further that might synthesize RARA active ligands in BMMw, we generated UGN/FAP cells. When treated with liarozole, these cells induced GFP expression, and the effect of liarozole was abrogated by DEAB, as expected (Fig. 4A , column 2 vs. columns 5 and 6). Transfection of an Aldh3b1 expression vector led to DEAB-insensitive Gal4-RARA transactivation and GFP expression, whereas transfection of Aldh9a1, Akr1a1, Akr1b8, or 2810405K02Rik did not (expression plasmids for Akr1a4 were not commercially available, and we tested Akr1a1, which is closely related and has a human homolog, whereas Akr1a4 does not; Fig. 4A ). Two additional Aldhs that showed differential but low expression in macrophages (Fig. 3D ) was also examined (Aldh7a1 and Aldh8a1). When triple transfected with the UAS-GFP reporter and the Gal4-RARA expression vector into 293T cells, only Aldh7a1 modestly augmented GFP output and only in the presence of liarozole (Fig. 4B) .
The effects of Aldh3b1 transfection were inhibited by 2 different RARA antagonists (Ro41-5253 and BMS493; Fig. 4C ). Furthermore, Aldh3b1 cotransfection increased the activity of Gal4-RARA but not Gal4-RXRA, suggesting that Aldh3b1 cotransfection results in synthesis of natural RARA-specific ligands that do not nonspecifically cross-react to transactivate the closely related Gal4-RXRA (Fig. 4D) . We also compared the activity of mouse Aldh3b1 and human ALDH3B1 in RARA ligand production. We observed that human ALDH3B1 had less activity, and the C465S mutation that prevents enzyme prenylation also prevented synthesis of RARA ligands in 293T cells (Fig. 4E) [33] .
ALDH activity of Aldh3b1 in vitro
We investigated the ALDH activity of mouse Aldh3b1 and human ALDH3B1 in vitro. We overexpressed mouse Aldh3b1 and human ALDH3B1 in 293T cells. We detected the ALDH activity of the protein by monitoring the fluorescence of the NADH product (excitation at 356 nm and emission at 460 nm) in increasing concentrations of octanal, as described previously [33] . We observed that mouse Aldh3b1 (V max = 4.55 6 0.019) had higher ALDH activity than human ALDH3B1 (Vmax = 3.1 6 0.017) when using octanal as a substrate (Fig. 5A) . We also detected endogenous mouse Aldh3b1 activity by use of the Kit + progenitor cell lysate and BMMw lysate (Fig. 5B) . We observed higher V max in BMMw vs. Kit + progenitor cells (3.5 6 0.27 vs.
2.4 6 0.25) and lower K m (6.5 6 2.1 vs. 28.9 6 8; Fig. 5B , inset, Lineweaver-Burk plot). These data are suggestive of lower concentrations of ALDH enzymes with lower affinity for octanal in Kit + progenitor cells vs. BMMw and are consistent with higher expression of Aldh3b1 in BMMw vs. Kit + progenitor cells. We performed MS on media from UGN/FAP stable 293T cells transfected with mouse Aldh3b1 expression plasmid. We found that nanomolar concentrations of ATRA could be detected in the media of untreated UGN/FAP cells, which decreased with DEAB treatment, and that Aldh3b1 transfection abrogated the effects of DEAB treatment and resulted in restoration of ATRA levels (Fig.  5C) . Importantly, the concentrations we observed match the dynamic range of RARA dissociation constant using radiolabeled ATRA (0.2 nM) [56] and the MSCV-Gal4-RARA-IC EC 50 we have observed in Kit + bone marrow cells ex vivo [30] . Similar results were observed when cell pellets were analyzed for intracellular ATRA (Fig. 5D ).
Aldh3b1 knockdown affects synthesis of RARA active ligands in BMMw
To study the function of endogenous Aldh3b1 in BMMw, we knocked down Aldh3b1 using siRNA ( Fig. 5E; schema) . Results from a Western blot assay demonstrated incomplete reduction in Aldh3b1 expression (Fig. 5F ). Following retroviral transduction of MSCV-Gal4-RARA-IC and treatment with retinal, we observed a reduction in the percentage of GFP + cells and in the MFI of GFP on a per-cell basis (Fig. 5G and H) , suggesting that Aldh3b1 contributes directly to RARA ligand synthesis in mouse BMMw.
Expression patterns of Aldh3b1, Aldh1a1, Aldh1a2, and Aldh1a3
We assessed the expression of Aldh3b1, Aldh1a1, Aldh1a2, and Aldh1a3 in mouse and human hematopoietic cells using previously published datasets (Supplemental Figs. 2 and 3 ) [57] [58] [59] . We found that Aldh3b1 was dynamically regulated during myelopoiesis, with higher expression in mature granulocytes in mice and in promyelocytes in humans, and that it was also easily detected in diverse human leukemias by RNA-Seq, with highest expression in M4 myelomonocytic and M5 monocytic leukemia (Supplemental Fig. 2 ). In contrast, Aldh1a1 was expressed predominantly in KLS stem/progenitor cells and in megakaryocyte-erythroid progenitor cells in mice and in human CD34 + cells, with down-regulation during myeloid maturation and low but detectable expression in diverse acute myeloid leukemias (Supplemental Fig. 3A , D, and G). Aldh1a2 and Aldh1a3 tend to be expressed at lower levels in mouse and human bone marrow cells and undergo less dynamic regulation. Thus, in hematopoietic cells, Aldh3b1 expression is distinct from Aldh1a1, Aldh1a2, or Aldh1a3.
Absence of natural RARA ligands in hematopoietic cells in vivo
To evaluate whether natural concentrations of vitamin A are sufficient to induce in vivo retinoid synthesis in macrophages and bone marrow granulocytes (cells with the highest Aldh3b1 expression), we transduced UAS-GFP bone marrow Kit + cells with MSCV-Gal4-RARA-IC and transplanted these cells into lethally irradiated mice. After 6 wk engraftment, we analyzed peritoneal macrophages and bone marrow monocytes (Gr1 + CD11b + ). We observed populations of mCherry + cells that had been transduced with MSCV-Gal4-RARA-IC but only rare GFP dim cells, suggesting that intracellular retinoids are absent in these cells in vivo (Fig. 6A-D) . As a positive control, we treated mice daily for 3 d with ATRA in corn oil by gavage (the doses 50, 100, and 200 mg/d are approximately equivalent to 7.5, 15, and 30 mg/m 2 ). We observed a response beginning with the lowest dose and a dose-dependent increase in the GFP MFI and GFP percentage ( Fig. 6E-P) .
Consistent with these findings, ex vivo Kit + progenitor cells and BMMw were unable to synthesize RARA ligands from available precursors when cultured in 15% FCS, whereas 293T cells were able to do so ( Figs. 1 and 2) . Thus, even though BMMw and Kit + bone marrow cells express enzymes involved in retinoid synthesis and use these enzymes to synthesize retinoids ex vivo when exposed to free vitamin A precursors at expected serum-available concentrations, this does not translate into significant concentrations of intracellular retinoids in vivo in mice maintained on a vitamin A-sufficient diet.
STRA6 has been implicated as an important transporter of retinol/retinol-binding protein 4 complexes [60] [61] [62] . Like other groups, we observed that Stra6 could be detected easily in kidney tissue by RT-PCR but was nearly absent in BMMw (Fig. 7A) [63] . Therefore, we determined whether low expression of this transporter might act as the rate-limiting step for ATRA synthesis in BMMw. We transduced UAS-GFP BMMw with MSCV-STRA6-IRES-Cerulean, sorted Cerulean-positive and -negative cells, and then transduced these cells with MSCV-Gal4-RARA-IC (Fig. 7B,  schema) . We found that simple overexpression of STRA6 was not sufficient to enable intracellular ATRA synthesis using available vitamin A precursors in the FCS (Fig. 7C vs. E) . Furthermore, we observed no effect following treatment with additional mouse serum (Fig. 7D vs. F) .
Finally, we evaluated whether hematopoietic stress, in the form of recovery from lineage-restricted stimulation, resulted in activation of necessary pathways for intracellular synthesis of ATRA (or other natural RARA ligands) in hematopoietic cells. We transduced UAS-GFP bone marrow Kit + cells with MSCVGal4-RARA-IC, as before, and transplanted these into lethally irradiated recipient mice. Following engraftment, cohorts of 3 or more mice were treated with the following: 5FU to induce pancytopenia and stem cell expansion; phenylhydrazine to induce hemolytic anemia and erythroid progenitor expansion; G-CSF to induce granulopoiesis, myeloid expansion, and stem cell mobilization; inflammatory triggered granulopoiesis via Ova-alum immunization; or neuraminidase to induce thrombocytopenia and megakaryocyte expansion. We found that none of these hematopoietic stimuli resulted in hematopoietic intracellular ATRA synthesis or synthesis of other RARA ligands (Fig. 8) .
DISCUSSION
RARA is the target of at least 10 fusion proteins that lead to APL [14] [15] [16] , and RARA expression increases dramatically during myeloid maturation [1] . Many of the X-RARA fusions have been proposed to act by reduced sensitivity to retinoid-dependent differentiation programs (a dominant-negative effect) [64] [65] [66] . However, enzymatic pathways required for retinoid synthesis have not been defined in primary hematopoietic cells.
In this study, we found that 2 different enzymatic pathways can be used for the synthesis of ATRA: DEAB-sensitive enzymes (Aldh1a1, Aldh1a2, and Aldh1a3) are principally used in dividing hematopoietic progenitor cells, whereas mature BMMw use a DEAB-insensitive enzyme. Russo et al. [67] had noted previously that ALDH1A1 inhibition only led to a partial inhibition of retinal-induced maturation of HL60 promyelocytic cells, suggesting that alternative enzymes might exist to metabolize vitamin A derivatives in myeloid cells. We identified Aldh3b1 as an addition enzyme capable of ATRA synthesis in myeloid cells.
The expression of Aldh1a1, Aldh1a2, Aldh1a3, and Aldh3b1 is distinct but not mutually exclusive (Supplemental Figs. 2 and 3 ). Of note, the effect of diverse ALDH inhibitors on retinoid synthesis in Kit + progenitor cells was statistically significant but was rarely complete (Fig. 2B) , suggesting that these cells used predominantly DEAB-sensitive enzymes in retinoid synthesis, although low activity of DEAB-insensitive enzymes cannot be ruled out, and low-level expression of Aldh3b1 was also noted in these cells (Fig. 3C and D) . Several ALDH inhibitors exhibited a 
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small but reproducible effect on RyA in BMMw, consistent with low but detectable levels of Aldh1a3 in BMMw (Figs. 2B and 3A) .
The RNA expression profile showed that Aldh3b1 is also highly expressed in ex vivo-derived granulocytes and in mature neutrophils (Supplemental Figs. 1B and 2 ). RARA ligand synthesis from retinal demonstrated an intermediate phenotype, with partial sensitivity to DEAB, consistent with Aldh3b1 expression, and retained expression of Aldh1a1, which we observed (Supplemental Fig. 1) .
We observed differential expression of 3 other ALDH enzymes in BMMw vs. Kit + progenitor cells (Aldh7a1, Aldh8a1, and Aldh9a1). Whereas it is possible that these enzymes also contribute to ATRA synthesis in BMMw, several observations counter this possibility. ALDH7A1 and ALDH8A1 are inhibited by compounds to which BMMw were largely resistant (DEAB, citral, and disulfram) [68, 69] . Aldh7A1 has been implicated in lysine catabolism, and the active site is unlikely to tolerate longerchain fatty acids, such as retinal, whereas Aldh8a1 has low activity with retinal as a substrate [70] . Consistent with these previous findings, we observed little effect of Aldh7a1, Aldh8a1, or Aldh9a1 when cotransfected into a RARA ligand reporter assay (Fig. 4) , collectively suggesting that these enzymes are unlikely to participate in RARA ligand synthesis.
Alternative enzymatic pathways must also be considered. The intracellular RA level is balanced by synthesis and elimination as shown in Fig. 1B , schema. After retinol enters a cell, besides being oxidized by ADHs, it could be esterified by the enzyme lecithin:retinol acyltranferase [46] or diacylglycerol O-acyltransferase 1 [71] . However, our RNA profiling and real-time PCR data showed that these genes were not differentially expressed in Kit + progenitor cells and BMMw (Supplemental Fig. 4B , and data not shown). Finally, ATRA is known to be eliminated when oxidized by the CYP26 family. We found that Cyp26 was expressed at low levels and was not differentially expressed between the Kit + progenitor cells and BMMw in our expression profiling data (Supplemental Fig. 4A ).
ALDH enzymes have been implicated previously as the ratelimiting step in ATRA synthesis [25, 26] . However, despite expressing the necessary enzymes required for converting RyA, retinol, or retinal to ATRA, primary hematopoietic cells could not generate RARA ligands from vitamin A precursors available in FCS or mouse serum ex vivo or in vivo in mice fed a vitamin A-sufficient diet (Figs. 1C-F, each column 1, and 6A-D) .
In vivo vitamin A is largely protein bound, whereas the RyA, retinol, and retinal that we used to treat cells ex vivo were added as free molecules into the tissue-culture medium. Therefore, the rate-limiting step of intracellular retinoid synthesis may be the expression of retinoid-binding proteins and the channels necessary for the intracellular transport of protein-bound retinol. Under homeostatic conditions in vivo, these pathways are sufficiently inactive (or absent) to result in the absence of intracellular retinoids in diverse hematopoietic cells. Simple overexpression of STRA6 was insufficient to enable ATRA synthesis from serum-available vitamin A precursors in BMMw ex vivo (Fig. 7) , and we could identify no physiologic stress that induced the necessary pathways required for vitamin A transport and subsequent intracellular ATRA synthesis in hematopoietic cells in vivo (Fig. 8) .
Further evidence, suggesting that ALDH enzymes are not the rate-limiting step in ATRA synthesis in hematopoietic cells, is obtained by analyzing the expression patterns of ALDH genes in APLs (a leukemia that is sensitive to ATRA). ALDH1A1 and ALDH3B1 are expressed in APLs; we observed low but detectable expression of Aldh3b1 in mouse cathepsin G-PML-RARA leukemias (Affymetrix expression range 234-894; average 557; Supplemental Fig. 2B, column 1 ) and significant expression in human APLs (RNA-Seq range 5.1-22.29 fpkms; average 12.7; Supplemental Fig. 2D, column 4) . Likewise ALDH1A1, ALDH1A2, and ALDH1A3 transcripts are consistently detected in human APL (RNA-Seq range 0.009-4.6 fpkms, average 0.7; range 0-0.7, average 0.16; and range 0-1, average 0.3, respectively; Supplemental Fig. 3G-I ). As these leukemias are highly sensitive to ATRA (which causes differentiation and loss of self renewal), the expression of these enzymes further suggests that they are not the rate-limiting step in retinoid synthesis, and alternative mechanisms must be limiting the intracellular availability of vitamin A in hematopoietic cells in vivo.
High levels of ALDH gene expression and activity have been correlated with hematopoietic stem cells [25, 26, 53, [72] [73] [74] [75] . Observations that ATRA can augment stem cell function ex vivo [8, 76] and that Aldh1a1, Aldh1a2, and Aldh1a3 are expressed at lower levels in mature BMMw vs. heterogeneous Kit + progenitor cell populations might suggest that the stem cell-associated function of ALDH might occur through ATRA synthesis. However, our data suggest that hematopoietic cells (including KLS stem/progenitor cells) exist within a retinoid-deplete environment (Fig. 6A and ref. [30] ). Likewise, Aldh3b1 expression is largely restricted to granulocytes and macrophages (Supplemental Fig. 2 ), yet this does not result in intracellular ATRA synthesis in vivo (Figs. 6 and 8) . Therefore, the stemassociated function of ALDH and the granulocyte-associated function of Aldh3b1 are not likely to be through ATRA generation. Alternatively, other groups have suggested that these enzymes may play important roles protecting cells against oxidative stress [77, 78] .
In sum, we have found that at least 2 distinct enzymatic pathways may be used in primary hematopoietic cells to synthesize ATRA from vitamin A metabolites. First, mouse bone marrow progenitor cells predominantly use a set of DEABsensitive enzymes (Aldh1a1, Aldh1a2, and Aldh1a3), whereas mature macrophages use an alternative, DEAB-insensitive pathway. We have identified Aldh3b1 as a likely candidate and shown that it is capable of ATRA synthesis in tissue culture. Although these enzymes are expressed in primary bone marrow cells, we found that this did not result in the synthesis of active intracellular RARA ligands in diverse hematopoietic cells, unless the cells were exposed to free vitamin A (RyA, retinol, or retinal). This suggests that in hematopoietic cells, the ratelimiting step in retinoid synthesis is likely to involve additional enzymes that facilitate the intracellular transport and release of vitamin A. Finally, even though RARA is dynamically regulated during hematopoietic cell differentiation and involved in diverse fusion oncoproteins, these studies suggest that hematopoietic cells lack intracellular retinoids and that adult hematopoietic RARA functions principally through ligandindependent activity.
